Important informations

Our researchers

Aucun résultat

Donna Senger

Donna Senger, PhD


Brain tumor microenvironment, Cancer, Drug discovery, Drug therapeutics, Fundamental research, Immunology, Innate immune cell recruitment, Neuroscience, Organ-selective metastasis, p75 neurotrophin receptor (CD271) in tumorigenesis, Pediatrics
  • Senior Investigator, Lady Davis Institute for Medical Research
  • Associate Professor, Gerald Bronfman Department of Oncology, McGill University

Contact details

(514) 340-8222 ext. 27840


Donna Senger is a Senior Investigator at the Lady Davis Institute for Medical Research, an Associate Professor in the Gerald Bronfman Department of Oncology at McGill University, and a founding scientist of Arch Cancer Therapeutics, a subsidiary of Arch Biopartners.

Professor Senger has had a long-standing interest on the development of pediatric and adult central nervous system (CNS) tumours including defining the molecular characteristics of invasive glioma, investigating cancer stem cells as therapeutic targets and understanding how the brain microenvironment impacts treatment.

More recently Pr. Senger’s research has focused on mechanisms important for the development of organ selective cancer metastasis, establishing in vivo cancer models for preclinical testing and identification and implementation of therapeutics for the treatment of sarcoma and metastatic melanoma.

Major Research Activities

 Donna Senger’s specific research interests include:

  • Pediatric and adult central nervous system tumours including defining the molecular characteristics with a specific interest in investigating the brain microenvironment and how it impacts the growth and progression of brain tumours. Pr. Senger has established a track record of taking some of the discoveries from the bench to the clinic.
  • Identification and implementation of therapeutics for the development of organ specific cancer metastasis with a particular emphasis in the areas of melanoma and osteosarcoma and the role inflammatory pathways play in these processes. Specifically, Pr. Senger is interested in identifying adhesion molecules expressed on specific organ endothelium.
  • Establishment of a preclinical in vivo drug-screening core and a “live” pediatric tumour bank that focuses on the establishment of pediatric-patient-derived-xenografts from rare cancers with a specific focus in the area of brain tumours, sarcomas and neuroblastoma. These activities support the Terry Fox PROFYLE (Precision Oncology for Young People) Model Systems Node.

Recent Publications and References